

Data Insights Application for Obesity

SP23 Capstone Design in ECE: *Final Design Report*

Group SP23-05

Team Members: Harini Senthilkumar, Abdul Uddin, Sahej Bansal, Taqiya Ehsan

Advisers: Dr. Sasan Haghani (Rutgers), John Canevari (Novo Nordisk), Shabana Motlani (Novo Nordisk)

Submitted in partial fulfillment of the requirements for senior design project
Electrical and Computer Engineering Department
Rutgers University, Piscataway, NJ 08854

Abstract—Comorbidity risk is an ever-present concern in patients with obesity, leading to chronic illnesses such as type II diabetes, hypertension, respiratory disease, cancer, stroke, etc. The comorbidity risks in patients with obesity are also correlated with their physique, social and economic situation, and other underlying health issues. Novo Nordisk, a leading global pharmaceutical company, has built a machine learning model that analyzes the comorbidity risks and costs associated with obesity based on input information of a patient’s clinical data, social determinants of health (SDoH), and other diagnosed health conditions. The goal of this project is to build a data insight application tool that provides a quantitative view into the comorbidity risks of a patient with obesity and the cost associated with their treatment. We develop a working iOS-based prototype of an end-user platform accessible from tablets. The application tool will primarily be used by market access representatives at Novo Nordisk in their outreach to healthcare payer programs, such as insurance companies and employers, to ensure an equitable access to medical solutions for all patients with obesity, staying true to the pharmaceutical industry’s market access standards.

Index Terms—Obesity, Comorbidity Risk, Healthcare, Pharmaceuticals, Market Access, Software Development, Data Analytic, Prediction Modeling, Data Visualization.

I. INTRODUCTION

A. Background

Trust for America’s Health recently reported that the obesity rate in America has consistently increased in the past decade, with no signs of plummeting. Nationwide, this rate is 41.9% with higher rates in rural areas than urban and suburban area [1]. Obesity is a multifaceted health condition that leads to different comorbidities. Comorbidity risk is an ever-present concern for patients with obesity, leading to chronic illnesses such as type II diabetes, hypertension, respiratory diseases, cancer, stroke, etc. The comorbidity risks in patients with obesity are also correlated with their physique, socioeconomic context, and other underlying health issues.

Obesity rises from relationships between “genetic, socioeconomic, and cultural influences” [2]. Obesity can also be onset by pharmacologic treatment or disease. Obesity is a risk factor for the development of comorbidity diseases. People who have obesity have reduced earning potential, higher healthcare costs,

and less school attendance. Obesity patients are at increased risk of morbidity from “dyslipidemia, T2D, hypertension, coronary heart disease, stroke, gallbladder disease, respiratory problems, sleep apnea, osteoarthritis, and some cancers” [2]. In addition to the onset of various diseases, obesity-related medical care costs in the United States “were estimated to be nearly \$173 billion” [3]. Annual nationwide productivity costs of obesity related absenteeism range from “\$79 - \$132 per individual” [3].

B. Problem Addressed

Novo Nordisk, a leading global pharmaceutical company, has built a machine learning model that analyzes the risks and costs associated with obesity based on input information of a patient’s clinical features, social determinants of health (SDoH) factors, and other diagnosed comorbidities. The machine learning model outputs enormous data sets which are hard to interpret and analyze. Regional Account Managers and other market access representatives would find it difficult to understand the technical output data sets. They need to leverage the large data sets to help aid in making important market access decisions. Market access in pharmaceutical refers to a company’s ability to provide appropriate treatments to patients.

To understand the need of the data insights application for obesity, market access research is necessary to understand the relationship between patients and treatment. Effective market access strategies are needed to keep drugs, therapies, and solutions affordable for consumers while providing constant access[4]. Also, market access is about generating and communicating data for the stakeholders involved in the adoption and funding of the drug. The two main activities of market access are national pricing/reimbursement and local negotiations/prescribing guidelines[5]. Before the patient receives access to the drugs, price and target patients must be agreed upon. The problem addressed with this project is to deal with accurately visualizing and filtering data that can be used by market access representatives in their outreach easily.

C. Objective

The goal of this project is to create a data insight application tool that provides a quantitative and visual overview into the comorbidity risks present in patients with obesity through the modification of clinical, SDoH, and associated risk factors. The application tool will provide concise and clear quantitative and visual insight into predicted comorbidity risks, cost of care estimation, and a regional context of SDoH factors. Our aim has been to develop a working iOS-based prototype of an end-user platform accessible from primarily tablets. The goal of the tool is to make the machine learning model predictions accessible for stakeholders to gain quantitative insights into risks faced by patients with obesity to guide data-driven conversations/discussions with healthcare payer programs about the risks and costs associated with it, while maintaining the pharmaceutical industry's market access standard.

D. Adopted Approach

The approach we are taking is using XCode and the Swift programming language to build the application that approaches the problem. Storyboard and SwiftUI of XCode are used to leverage various XCode components.

II. METHODS/APPROACH/RESULTS

A. Methods

1) *Conceptual Design*: This quantitative application tool was designed to provide the best possible experience for the regional account managers when using the application with clients. Using Figma, the application front end was prototyped in a few iterations and revisions. Figma is a collaborative web application for interface design. The final revision is shown in Figure 1. The design reflects the user flow for the regional account managers.




Fig. 1. Figma Wireframe

The initial planning of the design also included conforming to the recommended query structure from Novo Nordisk. This involved creating a login functionality as well as configuring states for our application when in use by regional account managers and market access personnel as displayed in Figure 2.




Fig. 2. Query Structure of the App

2) *UX Design*: To begin developing the application and finalizing designs, it was imperative to perform user experience research. This research would assist in development as we are able to consider our application's functionality and design choices through the eyes of the user and not just as developers. The research specifically involved pointing out goals, needs and pain points from the perspective of what the regional account manager would need from our application to be able to perform their function to the best of their ability. Therefore, we came up with the following points and considerations for an example user John Smith as shown in Figure 3.




Fig. 3. User Profile for John Smith

3) *Detailed design*: Figure 4 is the overall detailed design of the application that was implemented on XCode. The final detailed result of the project will be discussed in the results section.

Required Software Tools and Accessibility

- *XCode*: Xcode is Apple's integrated development environment for macOS. XCode provides developers a unified workflow for user interface design, coding, testing, and debugging. Accessible to anyone with a Macbook.



Fig. 4. Detailed Design

- *Swift*: Swift is a high-level compiled programming language developed by Apple and the open-source community.
- *Excel*: Excel is a spreadsheet developed by Microsoft and features calculation or computation capabilities, graphing tools, and pivot tables.

System Design and Implementation Challenges

- *Storyboard*: Storyboards help create all the screens of an application and interconnect the screens under one interface MainStoryboard. storyboard. It also helps in reducing the coding of pushing/presenting view controllers. Storyboard was used to design the login screen and user dashboard.
- *SwiftUI*: SwiftUI aids to highlights user experience and creating an interactive app. SwiftUI is easier to create a reusable view and avoid conflicts related with the simultaneous use of one project. SwiftUI was used for graphics and visualizations.

Time Constraints and their Impact on Design

- We had a limited time to complete the project. Our NDA with Novo Nordisk was signed at the end of February and so we only had a little over 2 months, until end of April, to completely design the project.

Technology Limitations

- Our most significant limitation was our lack of experience in iOS development. We had had a steep learning curve while desinging the application on iOS. Additionally one of our group members did not own/have access to a device running macOS which caused delays in starting development due to procurement issues.

B. Standards: Visual Identity

Novo Nordisk has a specific corporate visual identity. They have set guidelines to be followed for all products and applications that Novo Nordisk creates. Since we are creating an application for Novo Nordisk we have to meet certain requirements and guidelines. We followed three main elements in the corporate visual identity. The first is the logo; the logo of Novo Nordisk is a bull. The bull has been the symbol of the company since Novo Nordisk was founded in 1923. We placed

the logo as part of the app icon, login page, and insights/costs page. The second core element is maintaining Novo Nordisk colors: True Blue, Snow White, 18 different tints, and spot colors. We included True Blue and Snow White in most pages of the application. The third core element is the font. The corporate font is called Apis, Apis is a Sans-Serif style font. We made sure to use a Sans-Serif font as well.

C. Results

The quantitative application tool is an iOS application developed in Swift that provides key insights to Novo Nordisk associates about comorbidity risks associated with obesity. The application features a unique dashboard for each user. In order to access the dashboard, the Novo Nordisk market access representative enters their username and password. The application will authenticate the user by checking the login information against a database of users, and validate the information. Upon successful authentication, the dashboard will be presented to the user. The login in page can be seen in Figure 5.




Fig. 5. Login Screen

In Figure 6, the code for the connection between the login and user dashboard is shown. The username and password is authenticated and checked for accuracy. If it is right, then the dashboard screen appears. Else, an error is printed. In addition, if a user just hits login with an empty username and password field then an error appears as well.

```

85
86 func authenticateUser(username: String, password: String) -> Void {
87
88     var data = readDataFromCSV(fileName: "dummy_auth.csv")
89     data = cleanRows(file: data!)
90     let csvRows = csv(data: data!)
91     let database = csvRows[1...]
92
93     for info in database {
94         if info[0] == username {
95             if info[1] == password {
96                 performSegue(withIdentifier: "goToDashboard", sender: self)
97             } else {
98                 print("Error")
99                 return
100             }
101         }
102     }
103     print("Error")
104     return
105 }
106
107 }
108 }
109
110

```

Fig. 6. Login to Dashboard Code

Within the dashboard, there are two pages: Search and Explore. The Search page allows the user to specify a state

and zip code. The state field is a drop down scroll-able area that allows the user to scroll through and choose one of the fifty states, whereas the zip code is a text field in which a zip code can be typed. The user dashboard with can be seen in figure 4. The user has selected the state of Mississippi to look at. This is before the user hits the search button.




Fig. 7. Mississippi Selection

After specifying the information, the user can press the "Search" button, which presents numerous graphs and lists that the Regional Account Manager can use.

The insights page slides are broken down into different sections: graphs and lists.

Graphs: The first 3 page slides are graphs. The first graph is a double bar graph showing the true and predicted number of patients with varying comorbidities in the state. The double bar graph allows Regional Account Managers to trust and understand the machine learning output data that is powering our visualizations. The second graph is a simple pie chart that gives a quick breakdown of obesity in the state. The third bar graph shows the correlating percentages of the state population that has various social determinants of health, ranging from expenses spent on housing and education levels.




Fig. 8. SDoH Percentages for Mississippi




Fig. 9. Patient Levels for Mississippi




Fig. 10. Obesity in Mississippi

As an example, the SwiftUI code can be seen for the double bar graphic Figure 11. The SwiftUI function is called for the grouped bar graph for the correlating data and visualization specifics.

```

9 import SwiftUI
10 import SwiftUICharts
11
12 struct GroupedBarChartDemoView: View {
13
14     let data = makeData()
15     var body: some View {
16         VStack(
17             GroupedBarChart(chartData: data, groupSpacing: 25)
18                 .touchOverlay(chartData: data, unit: ".suffix(of: \"patients*\")")
19                 .yAxisGrid(chartData: data)
20                 .yAxisLabels(chartData: data)
21                 .yAxisTitle(chartData: data)
22                 .headerBox(chartData: data)
23                 .legends(chartData: data, columns: [GridItem(.flexible()), GridItem(.flexible())])
24                 .id(data.id)
25                 .frame(minWidth: 500, maxWidth: 680, minHeight: 400, idealHeight: 500, maxHeight:
26                     800, alignment: .top)
27                 .padding(.horizontal)
28         )
29     }
30 }
31

```

Fig. 11. Double Bar Graph Code

Lists: Following the graphs, there are 5 lists of top 10 SDoH drivers of comorbidities. The comorbidities are stroke, obesity-related cancers, respiratory diseases, and hypertension. There are different driving factors for each comorbidity. For example, the top 10 drivers of stroke for Mississippi include rate of stroke in population, percentage of population that is Hispanic, and rate of coronary heart disease. Whereas, the top 10 drivers of

hypertension for Mississippi include median hispanic household income, percentage of families in poverty, and rate of fitness and recreation centers. This is because different diseases have different social determinants that drive the total number of patients in that state.




Fig. 12. Top 10 SDOH Drivers in Mississippi

Additionally, there is an interpret page which explains the data by visualizing the associated comorbidity risks. Specifically, the interpret page details the cost incurred either by a patient (out of pocket), or insurance companies like Medicaid, Medicare, etc, due to obesity related comorbidities. This allows the user to know the potential cost savings if obesity is properly treated and the patient is cared for. Furthermore, the bars on the bottom indicate the percentage of the population who suffer from those comorbidities.

The second page of the dashboard is the Explore page, which allows the user to view brief SDOH information from across all states. The page visualizes the data analysis from the data set provided.




Fig. 13. Cost in Mississippi

Finally, the last page in our application is the Cost Savings page. This page is an anchor page in the sense that it is meant to create an impact on the client with the big bold




Fig. 14. Cost Selection

number in the center of the screen. The number that is shown on screen is the estimated annual cost of care for obesity related comorbidities in that specific state. It includes a disclaimer from Novo Nordisk’s side indicating that they are estimated costs and do not account for additional developed comorbidities. The user is able to filter for which payer they would like to view such as Patient Out of Pocket costs, Managed Medicaid costs, etc. The sliders at the bottom of the page display the percentage of people in that selected state that have the indicated obesity related comorbidity. The statistics are displayed only for the information of the client and user and are connected to genuine data.

```

56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

```

Fig. 15. Cost Selection

The overall architecture of the application can be described as a number of Swift Storyboards connected together. Storyboards were chosen because they allowed for rapid prototyping and development that mirrored the design on Figma. Specifically, Storyboards allow components to be dragged and dropped to specific locations, as opposed to coding those locations. Additionally, the Storyboards and their associated components could be linked to a ViewController file, which allows behavior to be programmed. This way, less time needed to be spent on getting the application to look as it did in the design, and more time was spent on the functionality.

III. COST AND SUSTAINABILITY ANALYSIS

The cost of mass production for this application tool can be contextualized under the three following divisions:

A. Economics Impact

1) *Materials and Equipment:* There is no initial cost of production for this application. We have used Figma and Xcode for developing it, which do not require any subscription. For mass deployment later it would be needed to subscribe to an Apple Developer Account which costs approximately \$99/year. Currently, Novo Nordisk stores all the patient data in a cloud storage platform called Snowflake, which is a partner of Amazon Web Services (AWS). However, in future, it might be required to purchase additional storage which can have a monthly cost between \$25 and \$50 depending on the volume of stored data.

2) *Labor:* The initial development of this application has been free of cost as we worked on it as a part of our Capstone project. However, after primary deployment, a full-time Software Engineer would need to be hired for regular maintenance and upgrades to the app. The standard annual salary of an entry-level Software Engineer is \$100K-\$120K.

3) *Facilities:* There was no cost associated with the initial development of the application as we worked on it on our personal devices and no new machine had to be purchased. But post-deployment, the maintenance of the application may entail a varying range of costs.

B. Social Impact

The high-level purpose of this application tool is to ensure access to appropriate medication and treatment options to as many people diagnosed with obesity in the most efficient way possible, by leveraging the power of data science and software engineering. This application provides an efficient tool for Market Access representatives to use in extending medical solutions equitably to people with obesity and related comorbidities. Through the succinct quantitative and visual insights, this application equips Novo Nordisk's Regional Account Managers and other Market Access representatives to formulate effective strategies for outreach to healthcare payer programs, like health insurance companies. In turn, this impacts what medical solutions are available to bariatric patients of varying socioeconomic statuses, diagnosed with different comorbidities. Novo Nordisk has been a champion in ensuring equitable choice of medical solutions to people from all demographics, and this application works as a powerful tool to reinforce that.

IV. CONCLUSION/SUMMARY

We have successfully developed a working model iOS application in Swift utilizing data from Novo Nordisk's machine learning model and provided an intuitive front-end for our users and NNI clients. The app provides a quantitative and visual overview into the comorbidity risks present in patients with obesity through the modification of clinical, SDoH, and associated risk factors. Through this application we aim to help

Novo Nordisk achieve their goal of providing and distributing equitable healthcare to the wider population of the United States. Helping combat obesity and its related comorbidities through our application would benefit affected individuals by allowing a healthier lifestyle and general well-being. In the future, the app can be additionally developed to add more visualizations and filters. In addition, the back end of the application can be connected to actual Novo Nordisk databases and storage units with live data.

ACKNOWLEDGEMENT

We would like to thank John Canevari and Shabana Motlani of Novo Nordisk for mentoring and sponsoring this project. We would also like to thank Dr. Sasan Haghani of Rutgers University for his guidance and insights.

REFERENCES

- [1] Trust for America's Health, "State of Obesity 2022: Better Policies for a Healthier America," 2022, 19th Annual Report.
- [2] M. D. Caroline M. Apovian, "Obesity: Definition, comorbidities, causes, and burden," 2016, AJMC.
- [3] Centers for Disease Control and Prevention, "Consequences of obesity," 2022, Overweight and Obesity.
- [4] Health Analytics, "Market Access Pharma," 2022.
- [5] PRMA Consulting, "What is market access?," 2023.